Previous close | N/A |
YTD return | N/A |
Expense ratio (net) | N/A |
Category | N/A |
Last cap gain | N/A |
Morningstar rating | N/A |
Morningstar risk rating | N/A |
Sustainability rating | N/A |
Net assets | N/A |
Beta (5Y monthly) | N/A |
Yield | N/A |
5y average return | N/A |
Holdings turnover | N/A |
Last dividend | N/A |
Average for category | N/A |
Inception date | N/A |
GUANGZHOU, China, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2023. Recent Business Updates Therapy Selection and Minimal Residual Disease (MRD) Personalized Minimal Residual Disease (MRD) product, brPROPHETTM supports advance
GUANGZHOU, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 20, 2023 at 10:00 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District,
GUANGZHOU, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the third quarter of 2023 before the U.S. market opens on November 30, 2023. Following the release, company management will host a conference call at 7:00 a.m. E